Animal trials of Bharat Biotech vaccine candidate Covaxin successful

Covaxin has demonstrated protective efficacy and immunogenicity in non-human primates in Phase I clinical trials in India. Covaxin, the indigenously developed Covid-19 vaccine, developed by the ICMR and Bharat Biotech International, is being tested at 12 institutes across India. The results of the first phase of testing are encouraging

A two-dose vaccination regimen of inactivated coronavirus vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally). The results showed protective efficacy, increasing coronavirus specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues of monkey.